Cheng، نويسنده , , Yung-Hsin and Hung، نويسنده , , Kuo-Hsuan and Tsai، نويسنده , , Tung-Hu and Lee، نويسنده , , Chia-Jung and Ku، نويسنده , , Ruy-Yu and Chiu، نويسنده , , Allen Wen-hsiang and Chiou، نويسنده , , Shih-Hwa and Liu، نويسنده , , Catherine Jui-ling، نويسنده ,
Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1 min at 37 °C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8 days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy.
LATANOPROST , Glaucoma , Hydrogel , DRUG DELIVERY